MENLO PARK, Calif.,
Jan. 12, 2017 /PRNewswire/
-- BioPharmX Corporation (NYSE MKT: BPMX), a specialty
pharmaceutical company developing products for the dermatology
market, will share research findings at this week's Orlando
Dermatology Aesthetic & Clinical (ODAC) Conference, which
suggest that topical minocycline may reduce P. acnes-induced
inflammation.
The data will be shared in a poster presentation titled
"Involvement of Sebaceous Gland in Acne Pathogenesis," at ODAC,
which is being held Jan. 13-16 in
Miami.
The study, part of BioPharmX's development program for its
unique BPX-01 topical minocycline formulation, suggests that
minocycline's anti-inflammatory properties may be delivered in a
topical formulation to target P. acnes-stimulated
sebocytes.
To effectively treat P. acnes with minocycline, the
product must also take advantage of minocycline's anti-inflammatory
properties. Recent studies have found that inflammation – long
thought to be a side effect of P. acnes – may actually be
one of the condition's underlying causes.
"Our research suggests that the anti-inflammatory benefit of
minocycline can be delivered preferentially to a target area using
BPX-01, our topical minocycline gel," said Kin F. Chan, executive
vice president of research and technology at BioPharmX. "The
potential of a topical targeted approach in unleashing both an
antibacterial and anti-inflammatory properties simultaneously is
critical to clearing acne lesions more effectively."
BPX-01 is the first and only stable hydrophilic (non-oil-based)
topical gel with fully solubilized minocycline that can penetrate
the skin to deliver the antibiotic to where the acne develops in
the pilosebaceous unit. The company's studies are designed to
confirm whether BPX-01 can effectively treat acne with lower, and
potentially safer, dosages of the antibiotic.
BioPharmX recently announced the on-time completion of
enrollment in the OPAL (tOPicAL Minocycline Gel) study – a Phase 2b
dose finding clinical trial to assess the efficacy and safety of
BPX-01 for the treatment of acne vulgaris.
The 12-week, multi-center, randomized, double-blind, three-arm,
vehicle-controlled OPAL study involves 225 individuals, aged 9 to
40, who have moderate-to-severe inflammatory, non-nodular acne
vulgaris.
The American Academy of Dermatology calls acne the "most common
skin condition in the United States," affecting 40 million to 50
million Americans. The U.S. market for acne medications is
estimated at $10 billion.
About BioPharmX® Corporation
BioPharmX Corporation
(NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical
company that seeks to provide products through proprietary platform
technologies for prescription, over-the-counter and supplement
applications in dermatology and women's health. To learn more about
BioPharmX, visit
www.BioPharmX.com.
Forward-Looking Statement
The information in this
press release contains forward-looking statements and information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the "safe harbor" created by those
sections. This press release contains forward-looking statements
about the company's expectations, plans, intentions and strategies,
including, but not limited to, statements regarding, the safety and
medical effects of BPX-01, the effect BPX-01 may have on the
treatment of acne, whether minocycline's anti-inflammatory
properties may be delivered in a topical formulation to target P.
acnes-stimulated sebocytes, commencement and results of future
tests involving BPX-01, continued and consistent results in future
tests of BPMX-01 and absence of side effects of future use of
BPX-01. These forward-looking statements may be identified by words
such as "plan", "expect," "anticipate," "believe," or similar
expressions that are intended to identify such forward-looking
statements. These forward-looking statements involve risks and
uncertainties, as well as assumptions, which, if they do not fully
materialize or prove incorrect, could cause our results to differ
materially from those expressed or implied by such forward-looking
statements. The risks and uncertainties include those described in
the company's filings with the Securities and Exchange Commission.
Given these risks and uncertainties, you are cautioned not to place
undue reliance on such forward-looking statements. The
forward-looking statements included in this news release are made
only as of the date hereof and the company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as may be required under applicable securities laws.
BioPharmX is a registered trademark of BioPharmX, Inc.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biopharmx-data-suggest-anti-inflammatory-activity-of-bpx-01-topical-minocycline-gel-300389976.html
SOURCE BioPharmX Corporation